Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2020

Open Access 01-12-2020 | Cancer Fatigue | Correction

Correction to: Impact of a combined multimodal-aerobic and multimodal intervention compared to standard aerobic treatment in breast cancer survivors with chronic cancer-related fatigue - results of a three-armed pragmatic trial in a comprehensive cohort design

Authors: Matthias Kröz, Marcus Reif, Augustina Glinz, Bettina Berger, Andreas Nikolaou, Roland Zerm, Benno Brinkhaus, Matthias Girke, Arndt Büssing, Christoph Gutenbrunner, On behalf of the CRF-2 study group

Published in: BMC Cancer | Issue 1/2020

Login to get access

Excerpt

Correction to: BMC Cancer 17, 166 (2017) …
Literature
1.
Metadata
Title
Correction to: Impact of a combined multimodal-aerobic and multimodal intervention compared to standard aerobic treatment in breast cancer survivors with chronic cancer-related fatigue - results of a three-armed pragmatic trial in a comprehensive cohort design
Authors
Matthias Kröz
Marcus Reif
Augustina Glinz
Bettina Berger
Andreas Nikolaou
Roland Zerm
Benno Brinkhaus
Matthias Girke
Arndt Büssing
Christoph Gutenbrunner
On behalf of the CRF-2 study group
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2020
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-020-07679-3

Other articles of this Issue 1/2020

BMC Cancer 1/2020 Go to the issue

Research article

Experiences and views of different key stakeholders on the feasibility of treating cancer-related fatigue

Research article

Racial differences in testicular cancer in the United States: descriptive epidemiology

Research article

Upregulation of pERK and c-JUN by γ-tocotrienol and not α-tocopherol are essential to the differential effect on apoptosis in prostate cancer cells

Research article

The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy

Research article

Does hypothyroidism increase the risk of breast cancer: evidence from a meta-analysis

Research article

A novel prognostic model predicting the long-term cancer-specific survival for patients with hypopharyngeal squamous cell carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits